Theravance Biopharma (TBPH) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Theravance Biopharma had a P/E ratio of 8.95, return on equity of 44.9% (up from -29.0%), debt-to-equity of 0.14 (down from 0.28) and a current ratio of 10.93 (up from 5.02). A current ratio of 10.93 means current assets exceed current liabilities.

Theravance Biopharma Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Valuation Ratios
P/E Ratio	8.95	-	-	0.86	-	-
Forward P/E	25.83	29.96	29.96	29.96	-	-
P/S Ratio	8.82	7.19	9.75	14.70	14.72	15.82
P/B Ratio	3.19	2.64	2.63	1.71	-2.40	-3.74
Price/Tangible Book	3.19	2.64	2.63	1.71	-	-
Price/FCF	3.98	-	-	-	-	-
Price/OCF	3.97	-	-	-	-	-
Enterprise Value Ratios
EV/Revenue	6.14	6.47	8.30	6.23	22.95	19.46
EV/FCF	2.77	-	-	-	-	-
Profitability & Returns
Return on Equity (ROE)	44.85%	-29.04%	-16.86%	-179.84%	-	-
Return on Assets (ROA)	-0.54%	-7.21%	-6.78%	-10.07%	-35.20%	-42.38%
Return on Invested Capital (ROIC)	-3.66%	-28.60%	-32.89%	-32.78%	-71.83%	-
Return on Capital Employed (ROCE)	-0.80%	-13.20%	-15.00%	-13.70%	-75.10%	-86.10%
Leverage & Solvency Ratios
Debt/Equity	0.14	0.28	0.23	0.12	-1.98	-2.23
Debt/FCF	0.18	-	-	-	-	-
Liquidity Ratios
Current Ratio	10.93	5.02	5.39	12.31	4.26	3.18
Quick Ratio	10.73	4.89	4.84	11.99	3.20	2.93
Efficiency Ratios
Asset Turnover	0.26	0.17	0.12	0.10	0.13	0.16
Yield & Distribution Ratios
Earnings Yield	11.17%	-12.19%	-9.86%	115.58%	-24.49%	-24.45%
FCF Yield	25.16%	-2.56%	-5.27%	-24.86%	-25.94%	-22.61%
Buyback Yield	-5.45%	11.67%	24.85%	-5.95%	-11.41%	-12.11%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Theravance Biopharma Financial Ratios

What is Theravance Biopharma's P/E ratio?

Theravance Biopharma's P/E ratio was 8.95 for fiscal 2025 (period ended Dec 31, 2025).

What is Theravance Biopharma's return on equity?

Theravance Biopharma's return on equity (ROE) was 44.9% for fiscal 2025 (period ended Dec 31, 2025). It was -29.0% a year earlier.

What is Theravance Biopharma's debt-to-equity ratio?

Theravance Biopharma's debt-to-equity ratio was 0.14 for fiscal 2025 (period ended Dec 31, 2025). It was 0.28 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition